With the coronavirus spreading at alarming levels, IMANA recognized the pressing need to provide factual and reassuring information to help communities understand the disease, its incidence, and its public health impacts. We are proud to present Dr. Daniel C. Brennan, Director of Johns Hopkins Transplant Comprehensive Center and Professor of Medicine, to discuss how the pandemic has impacted organ donation and transplantation, in addition to showing evidence-based research for clinicians, potential donors, and transplant candidates.
Dr. Brennan is a world-renowned scientific leader, published in the New England Journal of Medicine and conducting several NIH funded clinical trials.
00:04 Intro
00:25 Speaker introduction
02:18 COVID-19 and KT: What we need to know
03:26 COVID-19 cases and deaths
04:25 The US response to COVID-19
04:55 Number of transplants per week in the US
05:48 COVID-19 patients in Wuhan, China
06:04 COVID-19 Italian kidney transplant experience
07:25 COVID-19 in UK kidney transplant
08:05 Experience of COVID-19 pandemic in New York
08:40 NYC kidney transplant recipients
09:22 COVID-19 is a systemic disease
10:06 Renal histopathology of patients with COVID in China
10:49 Acute kidney injury in COVID-19
13:03 Detection methods for SARS-CoV-2
13:28 Virus nucleic acid tests using RT-P
13:32 SARS-CoV-2 and specimen types
14:18 Viral shedding and clinical presentation of COVID
14:49 SARS-CoV-2 shedding in KT recipients
15:25 Antibody tests for COVID
15:37 Screening and tests for organ donors
16:39 Donors with previous COVID infection
17:34 Living donors
18:09 Treatments of COVID
18:20 Possible targets of anti-COVID drugs
19:16 COVID-19 states and therapeutics in native and immunosupressed states
20:45 Lopinavir-Ritonavir treatment in adults hospitalized with severe COVID-19
20:57 Hydroxychloroquine in patients with mild to moderate COVID
21:15 Hydroxychloroquine in hospitalized patients with COVID
21:22 Remdesevir for patients with severe COVID
21:40 Remdesevir, clinical improvements on patients with severe COVID-19
21:49 Remdesevir for the treatment of COVID
22:10 Remdesevir shortens recovery time
23:05 Efficacy of Remdesevir in hospitalized COVID-19 patients
23:37 Adverse effects of Remdesevir
23:39 Corticosteroid treatment for virus-induced lung injury
24:24 Dexamethasone in hospitalized patients with COVID
25:13 Dexamethasone in SOT recipients
25:45 Pharmacologic management of patients with COVID
26:26 Cytokine release syndrome
27:26 Symptoms of CRS
27:55 Tocilizumab among patients with COVID-19 in ICU
28:20 Tocilizumab for severe COVID in SOT recipients
29:00 Convalescent plasma therapy
30:30 Mortality and igG antibody levels in the transfused plasma in hospitalized patients with COVID
30:59 Convalescent plasma therapy in patients with severe COVID
31:56 Treatment with convalescent plasma in SOT recipients with COVID-19
32:18 Monoclonan antibodies against SARS-CoV-2
32:46 Potential targets to curtail COVID-19
33:18 Concomitant medication in patients with COVID
33:22 ACE2 and ACEI/ARBs in patients with COVID
33:38 Possible effects of RAS inhibition on COVID
34:16 ACE2 and ACEI/ARBs in patients with COVID
34:39 Vitamin D levels in countries with COVID
35:51 Vitamin D deficiency and outcome in COVID patients
36:39 Vitamin D status and other clinical characteristics
37:13 Aspirin use in hospitalized patients with COVID
39:00 Management of immunosuppression for KT recipients with COVID-19
39:51 Cyclosporin and FK-506
41:28 Induction and steroids
43:06 COVID-19 and transplant: scales of decision making
43:11 COVID-19 outcomes for KT and KT recipients
43:39 Waitlist management
43:43 Organ selection
43:48 Immunization approaches
44:09 Coronavirus vaccine tracker
44:44 Diverse types of vaccines: advantages and disadvantages
45:16 Immune responses by vaccines
45:30 Development of vaccine candidates
46:08 Masks, social distancing, hand hygiene
47:04 Johns Hopkins COVID patients
48:22 Johns Hopkins approach to COVID
49:50 Johns Hopkins COVID treatment
51:32 Outpatient management for KT recipients
52:00 CTC COVID clinical activities
52:37 Strategies for safer living during the COVID-19 era
Q&A
53:11 With winter around the corner, do you suggest patients start taking Vitamin D?
54:23 Are vaccines safe for immunocompromised patients?
55:45 What is the timeline of the vaccine distribution to these immunocompromised patients?
56:48 Are any of the caregivers of these immunocompromised patients getting the vaccine at the same time?
57:36 For transplant patients who don’t have any severe symptoms, do they have to get hospitalized?
58:43 For primary care doctors who are the first in line taking care of their own patients, should they be checking these anti-inflammatory markers?
59:25 With the current situation of COVID, how do donors and recipients seek out transplant evaluations?
#imana #covid19
